Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Lantern Pharma announced agreements with contract manufacturing companies for process development and manufacturing for two of Lantern's oncology drug candidates, LP-300 and LP-184.
read more
Wednesday, November 01, 2017
Lannett has entered into a settlement and license agreement with Celgene Corporation that resolves patent infringement litigation in the U.S. related to Celgene's Thalomid.
read more
Wednesday, April 08, 2020
Lannett is set to meet with the FDA on June 9, 2020 to plan next steps for the clinical advancement of its biosimilar insulin glargine partnered product candidate.
read more
Lannett Company has announced plans to co-develop a generic insulin pharmaceutical product for the U.S. market with its strategic partner in China, YiChang HEC ChangJiang Pharmaceutical Co., Ltd, an HEC Group company.
read more
Monday, December 23, 2019
Lannett has received approvals from the FDA of its ANDAs for Butalbital, Acetaminophen and Caffeine Capsules.
read more
Monday, February 22, 2016
Lannett Company has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray USP, 5 mg/spray and 20 mg/spray, the therapeutic equivalent to the reference listed drug...
read more
Lannett Company said that its distribution agreement with Jerome Stevens Pharmaceuticals, which expires on March 23, 2019, will not be renewed.
read more
Lannett said representatives from the company spoke with and received guidance from the FDA on the clinical advancement program of its biosimilar insulin glargine partnered product candidate.
read more
Lannett has entered into an exclusive perpetual licensing agreement with Andor for Methylphenidate Hydrochloride ER tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54 mg strengths.
read more
Wednesday, January 23, 2019
Lannett entered into an agreement with a strategic alliance partner to be the exclusive U.S. distributor of Trientine Hydrochloride Capsules, 250 mg.
read more
Wednesday, August 28, 2019
Lannett has entered into an agreement with Sinotherapeutics to be the exclusive U.S. distributor of Posaconazole Delayed-Release Tablets 100mg.
read more
Lannett announced it has entered into a future exclusive supply and distribution agreement for the approved Levothyroxine Sodium Tablets USP.
read more
Lannett Company has entered into a three-year agreement with Elite Pharmaceuticals to be the exclusive U.S. distributor of a Dantrolene Capsules 25 mg, 50 mg and 100 mg.
read more
Monday, November 12, 2018
Lannett Company has entered into an agreement with Amneal Pharmaceuticals with regard to Levothyroxine Sodium Tablets USP.
read more
Friday, December 22, 2017
Lannett announced its board of directors has named Timothy C. Crew as the company's CEO, effective January 2, 2018.
read more